On Nov. 15, 2023, FDA approved Defencath (taurolidine and heparin), for a limited and specific population of patients. Defencath is a catheter lock solution (CLS) indicated to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC).

Defencath is the third drug to receive approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) and is manufactured for CorMedix Inc.

Visit the Notable Approval for additional information about Defencath, including prescribing information.